Bispecific caninized antibodies for treating atopic dermatitis
AssigneeIntervet Inc.
InventorsMohamad Morsey, Yuanzheng Zhang, Anasuya Saha
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions for treating canine atopic dermatitis that comprise a caninized anti-proliferative antibody, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further relates to compositions that comprise a bispecific antibody that comprises a caninized anti-pruritic antibody and a caninized anti-proliferative antibody or alternatively a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody.
Claims6
A bispecific antibody comprising a monomer of a caninized anti-pruritic antibody and a monomer of a caninized anti-inflammatory antibody;
- wherein the caninized anti-pruritic antibody is a caninized interleukin-31 receptor alpha (IL-31RA) antibody and the caninized anti-inflammatory antibody is a caninized interleukin-4 receptor alpha (IL-4R alpha) antibody;
- wherein the caninized IL-4R alpha antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:
- 4 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 18;
- and
- wherein the caninized IL-31RA antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:
- 43 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 42 or SEQ ID NO:
- 44.
Dependencies are inferred from the claim text.